CD8A and graft versus host disease: Phase I studies in GVHD and solid organ transplantation have started with regulatory cells from different types (different CD4+ Tregs, macrophages, and DCs) without apparent toxicity (5–7), but to date, there are no clinical trials using CD8+ Tregs despite abundant literature in animals models (8–10).